Pharmaceuticals News and Research

RSS

Inovio's SynCon vaccine for cervical dysplasias and cancers granted U.S. patent

Inovio Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,168,769, covering Inovio's SynCon vaccine for cervical dysplasias and cancers caused by human papillomavirus (HPV).

2 May 2012

Almac acquires high-speed blister line for new Audubon packaging facility

Almac, a leading provider of contract services to the global pharmaceutical and biotech industries, is pleased to announce the acquisition of a state-of-the-art, high-speed blister line for their new 100,000ft2 US commercial packaging facility in Audubon, PA.

2 May 2012

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2012.

2 May 2012

Two MSU researchers invent protein purifier for pharma companies

Two Michigan State University researchers have invented a protein purifier that could help pharmaceutical companies save time and money.

2 May 2012

BioMed Realty first quarter total revenues increase 14.1% to $120.0M

BioMed Realty Trust, Inc., a real estate investment trust focused on Providing Real Estate to the Life Science Industry, today announced financial results for the first quarter ended March 31, 2012.

2 May 2012

Thermo Scientific launches Nicolet iS50 FT-IR spectrometer

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific Nicolet iS50 FT-IR spectrometer, the first research-grade FT-IR with one-touch operation.

From Thermo Fisher Scientific Inc. 2 May 2012

BD second quarter revenues increase 3.6% to $1.991 billion

BD, a leading global medical technology company, today reported quarterly revenues of $1.991 billion for the second fiscal quarter ended March 31, 2012, representing an increase of 3.6 percent from the prior-year period, or 4.6 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 2 May 2012

Idera to present data from IMO-8400 preclinical studies on SLE, psoriasis at AAI meeting

Idera Pharmaceuticals, Inc. today announced that it will be presenting data from preclinical studies of its Toll-like receptor (TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus (SLE) and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications.

2 May 2012

Heart Rhythm Society launches Boston Citywide Awareness Campaign

Massachusetts Governor Deval Patrick has proclaimed May to be Cardiac Arrhythmia Awareness Month, calling attention to the need for greater public awareness throughout the Commonwealth about two serious heart rhythm conditions, atrial fibrillation and sudden cardiac arrest. To support consumer education about these potentially life-threatening disease states, the Heart Rhythm Society (HRS) has launched a Boston Citywide Awareness Campaign to increase knowledge about symptoms, warning signs and available treatment options.

2 May 2012

InSite Vision first quarter total revenues decrease to $2.3 million

InSite Vision Incorporated today reported financial results for the quarter ended March 31, 2012. Total revenues for the first quarter of 2012 were $2.3 million, a decrease of $0.8 million from the same quarter of 2011.

2 May 2012

AmerisourceBergen acquires World Courier Group

AmerisourceBergen Corporation today announced that it has completed the previously announced acquisition of World Courier Group, Inc., a privately held leading global specialty transportation and logistics provider for the biopharmaceutical industry.

2 May 2012

Antibiotic effective for plague gets FDA nod

Federal regulators – The Food and Drugs Administration (FDA), have approved use of an antibiotic to treat plague, an extremely rare, sometimes-fatal bacterial infection.

30 Apr 2012

FDA approves Levaquin for plague

The U.S. Food and Drug Administration today approved Levaquin (levofloxacin) to treat patients with plague, a rare and potentially deadly bacterial infection. The agency also approved the drug to reduce the risk of getting plague after exposure to Yersinia pestis, the bacterium that causes the disease.

30 Apr 2012

Kadimastem, Merck Serono enter agreement for MS drug-screening platform

Kadimastem, an Israeli Biotechnology company that develops human pluripotent stem cell-related products, today announced the signing of a five year framework agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

30 Apr 2012

Rexahn obtains additional patent coverage for anti-cancer candidate RX-1792 in Japan

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued to the Company patent No. 4,934,432, entitled "Quinazoline Derivatives and Therapeutic Use Thereof."

30 Apr 2012

JCO publishes Syndax erlotinib-entinostat Phase 2 study for advanced non-small cell lung cancer

Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).

30 Apr 2012

Teva, Mylan settle patent infringement litigation for Nuvigil

Teva Pharmaceutical Industries Ltd., one of the world's largest producers of pharmaceuticals, announces that it has settled patent infringement litigation regarding U.S. Patent Number 7,132,570 (the "'570 patent") with respect to Mylan Inc.'s ANDA for Teva's wakefulness product NUVIGIL (armodafinil) tablets.

30 Apr 2012

Enrollment complete in Zalicus Synavive Phase 2b clinical trial for rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced it has completed enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).

30 Apr 2012

Watson first quarter net income increases 87% to $208.8 million

Watson Pharmaceuticals, Inc. today reported net income for the first quarter 2012 increased 87 percent to $208.8 million or $1.64 per diluted share on a non-GAAP basis, compared to $111.9 million or $0.89 per diluted share in the first quarter 2011.

30 Apr 2012

Tolero granted exclusive global rights to commercialize MannKind's novel BTK compounds

Tolero Pharmaceuticals and MannKind Corporation today announced a license agreement granting Tolero exclusive worldwide rights to develop and commercialize compounds from MannKind's novel BTK (Bruton's tyrosine kinase) program, which are currently being developed for the treatment of hematological malignancies and inflammatory diseases.

30 Apr 2012